Core Viewpoint - BioCryst Pharmaceuticals will report its first quarter 2025 financial results on May 5, 2025, and will host a conference call to discuss these results and provide a corporate update [1]. Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with hereditary angioedema and other rare diseases [3]. - The company utilizes structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics targeting difficult-to-treat diseases [3]. - BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [3].

Company Summary - BioCryst (BCRX) is currently an intriguing investment choice due to solid earnings estimate revision activity and a favorable Zacks Rank [1][3] - Over the past month, current quarter estimates improved from a loss of $0.09 per share to a loss of $0.07 per share, while current year estimates increased from a loss of $0.07 per share to a loss of $0.06 per share [4] Industry Summary - The Medical – Drugs industry has a Zacks Industry Rank of 75 out of more than 250 industries, indicating strong positioning compared to other segments [2] - The positive trends in the Medical – Drugs space suggest that a rising tide may benefit multiple securities within the industry [2][5]

RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at http://www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology compa ...

For the quarter ended December 2024, BioCryst Pharmaceuticals (BCRX) reported revenue of $131.53 million, up 40.8% over the same period last year. EPS came in at -$0.13, compared to -$0.28 in the year-ago quarter.The reported revenue represents a surprise of +0.56% over the Zacks Consensus Estimate of $130.8 million. With the consensus EPS estimate being -$0.06, the EPS surprise was -116.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) has experienced a decline of 11.5% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, suggesting that selling pressure may be exhausting [2][4]. - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, signaling that bears may be losing control [3][4]. - This pattern can appear on various timeframes and is utilized by both short-term and long-term investors [4]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for BCRX, which is a bullish indicator for the stock [6]. - The consensus EPS estimate for the current year has increased by 18.4% over the last 30 days, indicating that analysts expect better earnings than previously predicted [7]. - BCRX holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

BioCryst Pharmaceuticals (BCRX) closed the last trading session at $8.28, gaining 4.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.25 indicates an 84.2% upside potential.The average comprises 12 short-term price targets ranging from a low of $8 to a high of $30, with a standard deviation of $6.48. While the lowest estimate indicates a decline of 3.4% from the current price ...

Group 1 - The biotech sector has experienced significant volatility, with investors often focusing on hyped plays rather than long-term winners [1] - BioCryst Pharmaceuticals is highlighted as a strong player in the rare disease market that has not yet received adequate market recognition [1] - The approach to investment in high-growth companies involves a combination of fundamental analysis and future trend prediction, emphasizing the potential of innovation for substantial returns [1]

After working as a Registered Nurse for several years, I transitioned into financial analysis, earning my MBA and developing expertise in healthcare & technology investments. Since 2017, I've published investment analyses on Seeking Alpha, focusing on thorough valuation modeling. My approach centers on examining core assumptions that drive stock valuations, particularly through detailed discounted cash flow analysis. I provide readers with various scenarios to help them understand potential outcomes. The pr ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Back in November 2023, I published a note on BioCryst (NASDAQ: BCRX ) to Seeking Alpha, assigning its stock a "Sell" rating. At the time, shares were priced at $5.5, and in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...